BridgeMD
New treatment option for Gingival Recession
Official title Treatment of Gingival Recession With Tunnel Technique Using Connective Tissue Graft and Injectable Platelet Rich Fibrin
ClinicalTrials.gov ID: NCT06646432
What this study is testing
- What it's testing
- Gingival recession is a common periodontal problem. Consequences include teeth sensitivity, poor esthetics and impaired oral hygiene access.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 and older
You may be able to join if
- More than 21 years old
- Systemically healthy
- Presence of Miller class I/II gingival recession
- Presence of identifiable CEJ
You likely can't join if
- Smoking
- Systemic disease that contraindicates surgical procedures.
- Poor compliance with oral hygiene measures
- Necrotizing gingival conditions
- Ongoing active periodontitis
The study team makes the final eligibility decision.
Where it's taking place
- Ismailia, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 21 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ismailia, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.